Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biocon Ltd.

www.biocon.com

Latest From Biocon Ltd.

Mylan Insists Complex Generics Strategy Is Poised To Deliver

With one high-profile approval in its pocket – a version of Teva's blockbuster Copaxone – Mylan's management believes its strategy of investing in complex generics and biosimilars will help the company navigate challenges in the US generic market.

Generic Drugs Biosimilars

USV Seeks To Progress Oral Insulin In India

USV Ltd expects to progress studies with Diabetology’s oral insulin in India, five years after the companies signed a licensing deal in 2012. The oral insulins space has seen mixed progress in the recent past, with a high profile pullback and funding support in another instance for an oral insulin candidate.

Research & Development Metabolic Disorders

Four Biosimilar Pegfilgrastims Under EU Review After Sandoz Re-Submits Zioxtenzo

The EMA’s scientific committee, the CHMP, now has four biosimilar versions of Amgen’s neutropenia drug Neulasta (pegfilgrastim) under review, after Sandoz re-submitted its product at the end of October.

Biosimilars Drug Review

Biosimilar Development Meetings At US FDA Not Just For Talking Similarity

Sponsors shouldn't wait until pre-submission meetings with the agency to discuss manufacturing, packaging and other matters unrelated to similarity data, FDA's Leah Christl says in remarks seemingly aimed at calling attention to issues that can forestall approval.

Biosimilars Manufacturing
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Medical Devices
  • Pharmaceuticals
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • India
  • Parent & Subsidiaries
  • Biocon Ltd.
  • Senior Management
  • Arun ` Chandavarkar, PhD, CEO
    Siddharth Mittal, CFO
    Ravi Limay, Pres., Mktg.
    Narendra Chirmule, PhD, SVP & Head, R&D
  • Contact Info
  • Biocon Ltd.
    Phone: (91) 80 2808 2808
    20th KM Hosur Rd.
    Electronic City
    Bangalore , 560 100
    India
Advertisement
Advertisement
UsernamePublicRestriction

Register